Kloxxado® is a nasal spray containing naloxone designed for the emergency treatment of opioid overdoses. Kloxxado® delivers a higher concentration of naloxone than the well-known medication Narcan® to combat the rise of highly potent opioids like fentanyl.
Opioid overdoses can lead to severe respiratory depression, unconsciousness, and even death. Kloxxado®, with its rapid onset of action, works quickly to reverse these dangerous symptoms. This quick action is vital in overdose situations, providing an immediate response that can sustain an individual’s life until emergency medical help arrives.
Common symptoms of an opioid overdose may include:
If you or someone you know is struggling with opioid addiction, Porch Light Health is here to help. We offer a range of outpatient services tailored to individual needs, ensuring that each person’s path to recovery is supported and sustainable.
New Patient Registration | Call: 866-394-6123
The active ingredient in Kloxxado®, naloxone, works by quickly displacing opioids from the receptor sites in the brain. This action helps to reverse the life-threatening effects of an opioid overdose, and its effects are usually evident within minutes, making it a crucial tool in emergencies.
Kloxxado® operates through a clear and direct mechanism of action, primarily targeting the central nervous system’s opioid receptors. These receptors are the sites where opioids bind to produce their effects, which can include pain relief, sedation, and, unfortunately, in cases of overdose, severe respiratory depression. When Kloxxado® is administered, its active ingredient, naloxone, swiftly travels to these receptors.
Naloxone has a higher affinity for these opioid receptors than most opioids do, meaning it can effectively compete with and displace opioids from these receptor sites. Once naloxone binds to the receptors, it blocks and reverses the effects of the opioids present in the system. This displacement can reverse the life-threatening symptoms of an opioid overdose, particularly respiratory depression, which is the primary cause of death in these situations.
Kloxxado® is uniquely formulated as a nasal spray, providing a straightforward and non-invasive method of administration. This approach allows for rapid application in emergencies, eliminating the need for injections or complex medical procedures.
The nasal spray format of naloxone is particularly beneficial in public settings or at home, as it can be used by anyone, including those with no medical background. Its user-friendly design ensures that Kloxxado® can be administered quickly and efficiently, which is paramount in a life-threatening overdose situation. The simplicity of the nasal spray also helps reduce hesitations or errors that commonly occur in high-stress emergencies.
Both Kloxxado® and Narcan® are nasal sprays that contain naloxone, a medication used for reversing opioid overdoses. Kloxxado® differs from Narcan® due to its higher concentration of naloxone. Each spray of Kloxxado® delivers 8 milligrams of naloxone, in contrast to Narcan®, which provides 4 milligrams per spray. The higher dosage of naloxone in Kloxxado® was developed partly in response to studies such as one published in the Harm Reduction Journal, which highlighted that opioid overdoses often require multiple doses of lower-concentration naloxone, such as Narcan®, for effective reversal.
Kloxxado®’s higher-strength formulation is designed to elicit a more potent response, which is particularly helpful in cases with highly potent opioids like fentanyl. It provides a stronger, potentially more effective response in a single dose. This is pivotal given the increasing potency of opioids commonly involved in overdoses today.
The U.S. Food & Drug Administration approved Kloxxado®, a higher dosage of naloxone, for emergency treatment of known or suspected opioid overdose in 2021. Similar to Narcan®, the accessibility of this medication is significantly enhanced because it can be obtained without a prescription in many places. Over-the-counter availability is a crucial aspect in combating the opioid crisis, allowing for quicker and broader access to lifesaving medication. By removing the barrier of needing a prescription, Kloxxado® becomes more accessible to the general public, including those who might be at risk of experiencing or witnessing an opioid overdose.
It’s important to note availability of over-the-counter (OTC) naloxone varies by state due to differing state laws and regulations. However, many states have implemented standing orders or other measures that allow pharmacies to dispense naloxone without an individual prescription.
The team at Porch Light Health understands that addressing opioid addiction requires a comprehensive approach. We offer Medication-Assisted Treatment (MAT) and addiction treatment in Colorado and New Mexico. Our programs offer a holistic and accessible approach to addiction treatment, incorporating a spectrum of services, including FDA-approved medications, counseling, and behavioral therapies in our clinic network of over 60 points of care.
If you or a loved one is struggling with opioid addiction, or if you want to learn more about tools like Kloxxado® and how they fit into a broader treatment plan, contact Porch Light Health today. Knowledge is power in the journey to recovery, and Porch Light Health is committed to being a part of your support system at every stage.
New Patient Registration | Call: 866-394-6123
Kloxxado® and Narcan® both contain naloxone, which can reverse opioid overdoses. The main difference lies in their formulation and dosage. Kloxxado® typically has a higher naloxone concentration per dose compared to Narcan®.
Kloxxado® is used to reverse the effects of an opioid overdose rapidly. It acts quickly to block the effects of opioids and can be life-saving in emergencies.
Kloxxado® is not classified as a controlled substance. It contains naloxone, a medication used in emergencies to treat opioid overdoses, and does not have the potential for abuse or addiction.
The U.S. Food and Drug Administration (FDA) approved Kloxxado® on April 30, 2021. This approval marked a significant step in providing a higher-dose naloxone option to address the increasing potency of opioids involved in overdoses and the growing need for effective emergency treatments.
